Development of a new surgical device for the treatment of left ventricular ischemia and aneurysm

左心室动脉瘤是心肌梗死的严重并发症。本研究利用啮齿类动物骨髓来源的干细胞，为开发一种新的外科补片-装置系统治疗左心室缺血和心功能不全进行了基础性研究。1.骨髓KSL细胞对小鼠去负荷心脏左心室缺血的影响。我们从同基因小鼠的骨髓中分离出KSL细胞（Lin-/c-kit+/Sca 1+），一种含有内皮和心肌祖细胞的组分，并将其移植到移植的LV中。KSL细胞移植受体显示冠状动脉血流量增加，伴有LV毛细血管密度和肌肉质量增加。结果表明，KSL-细胞移植通过改善冠状动脉循环，防止了左室收缩缺陷和去负荷心脏心肌萎缩。我们正在准备一份手稿，以显示KSL细胞作为材料产生LV-补片系统的强大效率。2.补片系统和大鼠模型的开发接下来，我们制备了模型动物。结扎刘易斯大鼠冠状动脉左前降支，造成心肌梗死和缺血。我们对缺血心脏进行了组织学分析，发现该模型适合作为手术治疗的受体。现在，我们继续使用来自大鼠骨髓的KSL细胞和可生物降解材料在体外开发贴片装置系统。

Aneurysm of the left ventricle (LV) is a catastrophic complication of myocardial infarction. In this study, we have performed a fundamental study using rodent bone marrow-derived cells for the development of a new surgical patch-device system to treat left ventricular ischemia and aneurysm.1.Effect of bone-marrow KSL cells on LV-ischemia in mouse unloading heart.Mouse recipient with isogenic heart transplantation in the abdomen shows sever ischemia in left ventricle of the transplanted heart. We have isolated KSL cells (Lin-/c-kit+/Sca1+), a fraction containing endothelial and cardiac muscle progenitor cells, from the bone marrow in isogenic mouse, and transplant them in the transplanted LV. The KSL-cell transfer recipient showed increased coronary blood flow accompanied by increased LV capillary density and muscle mass. The result indicates that the KSL-cell transfer prevents LV contractile defect and myocardial atrophy in unloading heart by an improving the coronary circulation. We are preparing a manuscript to publish to show the powerful efficiency of the KSL cells as a material to generate LV-patch system.2.Development a patch system and rat model.We next prepared a model animal. Lewis rat were received ligation of left anterior descending coronary artery to develop myocardial infarction and ischemia. We have done histological analyses of the ischemic heart, and found that the model was suitable as a recipient of the surgical treatment. Now, we continue the development of the patch device system in vitro using both KSL cells from rat bone marrow and biodegradable materials.